Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3157]

Multimodal AI model augments Oncotype DX in predicting distant recurrence in...

Dr Joseph Sparano - Icahn School of Medicine at Mount Sinai, New York, USA

Multimodal AI model augments Oncotype DX in predicting distant recurrence in HR+/HER2 node negative BC ( Dr Joseph Sparano - Icahn School of Medicine at Mount Sinai, New York, USA )

Higher tumour-infiltrating lymphocytes predict better pathologic response in...

Prof Sunil Badve - Emory University, Atlanta, USA

Higher tumour-infiltrating lymphocytes predict better pathologic response in HER2-positive breast cancer ( Prof Sunil Badve - Emory University, Atlanta, USA )

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in...

Dr Anjali Advani - Cleveland Clinic, Cleveland, USA

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in elderly patients with Ph+ ALL ( Dr Anjali Advani - Cleveland Clinic, Cleveland, USA )

Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2...

Dr Erika Hamilton - Sarah Cannon Research Institute, Nashville, USA

Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2-positive metastatic breast cancer ( Dr Erika Hamilton - Sarah Cannon Research Institute, Nashville, USA )

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to...

Prof Wojciech Jurczak - Maria Sklodowska-Curie National Research Institute of...

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to bendamustine plus rituximab ( Prof Wojciech Jurczak - Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland )

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in...

Dr John Burke - Rocky Mountain Cancer Centers, Aurora, USA

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma ( Dr John Burke - Rocky Mountain Cancer Centers, Aurora, USA )

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL

Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor...

Dr Keith McCrae - Cleveland Clinic, Cleveland, USA

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis ( Dr Keith McCrae - Cleveland Clinic, Cleveland, USA )

AI and pathology reveal higher late recurrence risk in invasive lobular breast...

Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer ( Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia )

Essential breast cancer medicines

Dr Didier Verhoeven, Prof Helena Earl, Prof Ahmed Magdy and Prof Luiz Gebrim

Essential breast cancer medicines ( Dr Didier Verhoeven, Prof Helena Earl, Prof Ahmed Magdy and Prof Luiz Gebrim )

Tec-Dara significantly improves PFS and OS compared to SoC in relapsed...

Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA

$Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma ( Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA )$

Black patients show inferior survival despite similar cytogenetics and...

Prof Shella Saint Fleur-Lominy - University of Maryland School of Medicine...

Black patients show inferior survival despite similar cytogenetics and treatment response ( Prof Shella Saint Fleur-Lominy - University of Maryland School of Medicine, Baltimore, USA )

More from ecancer